TickerTalks
Browse all tickers →
TickerTalks›$SEPN
SESEPN

Septerna Inc

$SEPN·$1.7B·Biotechnology·Healthcare
$37.45+3.1%YTD+38.8%1Y+55.9%
Price updated 1h ago·X counts updated 4d ago
SESEPN
$SEPNSepterna Inc
$37.45+3.11%7 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $SEPN on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

7X posts · last 7 days
Sep 28Oct 11

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $SEPN — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Septerna with 62% EPS surprise on pipeline progression — the specialty-biotech setup into Nov 9 earnings.

Septerna is a clinical-stage biopharma whose 2026 setup reflects pipeline progression plus comparative institutional-attention across the CRISPR/Valneva/WAVE/Septerna cohort.

  • The P&L is scaling off a tiny base: Q2 revenue grew massively to $27M at a -62.9% operating margin and EPS of -$0.29, with trailing EPS beats of 31.9% and 62.7% — these are the small-dollar surprise swings typical of a clinical-stage biopharma where quarterly numbers reflect expense accruals rather than operations.
  • The specific capital-markets positioning is substantive: CRISPR Therapeutics head-to-head framing plus Valneva and WAVE Life Sciences comparison coverage — three coordinated institutional-cohort-comparison datapoints.

At 60% of its 52-week range and 22% above the 200-day going into Nov 9 earnings, the setup is coiled on validation. A specific pipeline-progression commentary plus clean cash runway is the trigger for continuation; a safety signal or any specific competitive-dynamics within the cohort is the invalidation.

What to watch: Nov 9 Q3 earnings — pipeline-progression updates, cash runway, named partnership developments, and specific comparative-pipeline commentary. Named catalyst plus clean cash is the trigger; safety signal is the invalidation.

On the calendar: 2026-11-09 — Q3 earnings

event ahead 30dspecialty biotech

Read the AI verdict on $SEPN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing oral GPCR small molecule drugs targeting endocrine, metabolic, and inflammatory diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $SEPN.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $SEPN

Neutral — Clinical-stage biotech developing oral GPCR small molecule drugs targeting endocrine, metabolic, and inflammatory diseases.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+34.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-88.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-8.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-44.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
21.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-6.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
72.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 10, 2026$-0.29$-0.43+31.9%
Q1 2026May 12, 2026$-0.19$-0.51+62.7%
Q4 2025Mar 9, 2026$-0.24$-0.23-4.3%
Q3 2025Nov 10, 2025$-0.09$0.19-147.4%
Next earningsMon, Nov 9·consensus EPS $-0.41

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$26.7M+22375.6%0.0%-62.9%$-0.29$-22.2M
Q1 FY26$26.5M+12011.0%98.4%-50.1%$-0.19$-26.5M
Q4 FY25$24.1M+11276.4%100%-66.4%$-0.24$-15.1M
Q3 FY25$21.5M+12113.1%100%12.2%$0.18$168.8M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$96.0M$59.0M – $118.4M-$1.35-$2.28 – -$0.798
FY27$73.6M$59.5M – $89.9M-$2.28-$3.70 – -$1.387
FY28$67.0M$42.3M – $82.3M-$2.70-$4.25 – -$1.608
FY29$56.2M$35.4M – $68.9M-$3.72-$4.82 – -$1.936
FY30$86.8M$54.8M – $106.6M-$4.04-$5.24 – -$2.106

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.56%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-7.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+16.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 18.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.285-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 1Daniel D. LongSVP, Drug Discovery3.3K sh$126KSellAug 12Third Rock Ventures V, L.p.10% owner147.2K sh$7.4MSellAug 12Ra Capital Management, L.p.Director1.5M sh$63.5MSellAug 11Elizabeth BhattCOO25.0K sh$1.1MSellAug 3Daniel D. LongSVP, Drug Discovery3.3K sh$115KSellJul 15Elizabeth BhattCOO4.0K sh$136KSellJul 1Daniel D. LongSVP, Drug Discovery3.3K sh$115KSellJun 29Samira ShaikhlyChief People Officer2.2K sh$77KSellJun 22Daniel D. LongSVP, Drug Discovery15.0K sh$533KSellJun 12Samira ShaikhlyChief People Officer6.3K sh$219K
1–10 of 12
+ 19 other (10 exempts · 9 awards) in window

See when $SEPN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsSep 33
AI summary

Serpentine Energy (SEPN) filed a Form 3 for Rajiv Patni, newly appointed Chief Marketing Officer. Patni reported zero beneficial ownership of Serpentine securities as of the filing date. This is a routine initial ownership disclosure.

8-KPress release / Reg FDAug 258-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Septerna appointed Rajiv Patni, M.D. as Chief Medical Officer effective August 25, 2026, issuing a press release under Items 7.01 and 8.01. The appointment brings an industry-veteran physician executive to lead Septerna's clinical development. Standard CMO hire at a clinical-stage biotech; press release details Patni's background and strategic fit.

SC 13D/AActivist amendmentAug 14SC 13D/A
AI summary

RA Capital Management, L.P. (led by Peter Kolchinsky and Rajeev Shah) filed Amendment 1 to its Schedule 13D on Septerna, Inc. on August 12, 2026, disclosing shared beneficial ownership of 5,525,324 shares — 11.8% of SEPN's outstanding common stock. The position spans RA Capital Management L.P., the RA Capital Healthcare Fund, and principals Kolchinsky and Shah (all reporting the same 11.8% aggregate). RA Capital is a major life sciences investor known for concentrated long-duration bets; an 11.8% stake in this GPCR-targeted drug discovery company signals high institutional conviction.

8-KShareholder voteJun 308-K — Item 5.07: Shareholder vote
AI summary

Septerna (SEPN) held its 2026 Annual Meeting on June 26, 2026. Shalini Sharp, M.B.A. and Jake Simson, Ph.D. were elected to the Board as Class II directors for three-year terms. Additional proposals and vote tallies are in the filing.

+ 8 other (2 10-Qs · 2 earnings 8-Ks · 2 proxys · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

CRISPR Therapeutics (NASDAQ:CRSP) & Septerna (NASDAQ:SEPN) Head-To-Head Surveydefenseworld.net·18d agoAnalyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)defenseworld.net·22d agoComparing WAVE Life Sciences (NASDAQ:WVE) and Septerna (NASDAQ:SEPN)defenseworld.net·24d agoVIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 13,300 Septerna, Inc. $SEPNdefenseworld.net·30d agoSepterna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·35d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $SEPN on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport